06:01 PM EST, 01/08/2026 (MT Newswires) -- Merck & Co ( MRK ) is in talks to buy Revolution Medicines ( RVMD ) , the Financial Times reported Thursday, citing unnamed sources.

The deal, which could be announced after several weeks, is likely to be valued between $28 billion and $32 billion, according to the report.

If a deal is closed, Merck ( MRK ) aims to access Revolution Medicines' ( RVMD ) lead drug daraxonrasib, which targets a specific gene mutation for pancreatic cancers, and has won a fast-track review from the U.S. Food and Drug Administration.

Other large pharma companies are reported to be interested in Revolution.

Revolution shares jumped more than 18% in extended trading.

Merck & Co. ( MRK ) and Revolution Medicines ( RVMD ) didn't immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)